If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHNT.L Regulatory News (HNT)

  • There is currently no data for HNT

Trading Update

17 Dec 2019 07:00

RNS Number : 0634X
Huntsworth PLC
17 December 2019
 

 

17 December 2019

Trading Update

 

Huntsworth plc ("Huntsworth or the "Group"), the international healthcare and communications group, today issues a trading update for the 11 months to 30 November 2019.

 

·;

Group trading satisfactory, within market expectations

 

·;

Return to growth in Marketing

 

·;

Acquisitions successfully integrated and performing in line with expectations

 

·;

Cash flow strong and gearing expected to fall to c.1.6x at the year-end

 

 

Current Trading

The Group anticipates like-for-like revenue growth of c. 3% for the full year, with a small impact on margin as a result of investments in property and talent, and expects to report headline profit before tax within current market expectations* for the year to 31 December 2019.

As expected, the Marketing division saw an acceleration of growth over the second half of the year, although client-led project deferrals and product closures limited the level of growth to c. 3% across the half. Project wins were good, and the pipeline of opportunities is strong, especially in multi-service requirements where the additional capabilities of acquired businesses can be deployed, indicating further improvement and good prospects for 2020.

There was further good growth in the Medical division leading to c. 8% like-for-like growth for the full year. The Immersive division performed well against very strong comparatives and has secured a number of new mandates which indicate good growth prospects for 2020, although the cost of securing these mandates impacted profits.

The Communications division saw an acceleration of growth in the second half and will achieve full year revenue growth of c. 2% for the first time in several years.

 

Financial Position

The Group remains in a strong financial position, operating well within its £130m facility, and expects year end leverage to be c. 1.6x net debt to pro forma EBITDA**.

  

Outlook

The Group remains focused on delivering superior growth led by its healthcare agencies and recent acquisitions continue to complement this. Despite some currency headwinds as a result of the strengthening in sterling, management is confident about the Group's future trading and expects continued good growth across all of its businesses in 2020.

 

* Market expectations of Headline PBT range from £38.5m to £41.0m

** Pro forma EBITDA takes into account a full year's contribution from acquisitions made during 2019. Leverage is on a pre-IFRS 16 basis.

 

 

 Enquiries

 

 

Citigate Dewe Rogerson

020 7638 9571

Angharad Couch

Nick Reading

Elizabeth Kittle

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGGGGPPUPBGBQ
Date   Source Headline
26th Jul 20177:00 amRNSInterim Results for the six months to 30 June 2017
11th Jul 20172:28 pmRNSHolding(s) in Company
6th Jul 20172:04 pmRNSDirector/PDMR Shareholding
5th Jul 20177:00 amRNSAdditional Listing
4th Jul 20173:33 pmRNSHolding(s) in Company
3rd Jul 20177:00 amRNSAcquisition of The Creative Engagement Group
29th Jun 20175:53 pmRNSHolding(s) in Company
29th Jun 201712:33 pmRNSDisposal by BlueFocus
22nd Jun 20179:00 amRNSNotice of Interim Results
14th Jun 201711:27 amRNSHolding(s) in Company
2nd Jun 201711:07 amRNSScrip Dividend Alternative
25th May 20172:22 pmRNSResults of Annual General Meeting
25th May 20177:00 amRNSTrading Update
9th May 20175:38 pmRNSHolding(s) in Company
9th May 20179:13 amRNSDirector Declaration
5th May 20174:40 pmRNSSecond Price Monitoring Extn
5th May 20174:35 pmRNSPrice Monitoring Extension
28th Apr 20174:47 pmRNSHolding(s) in Company
28th Apr 201710:48 amRNSHolding(s) in Company
27th Apr 20178:59 amRNSDisposal and lock-up arrangement
25th Apr 20179:30 amRNSNotice of AGM
22nd Mar 201710:30 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSPreliminary results year ended 31 December 2016
16th Feb 20177:00 amRNSTrading update for year ending 31 December 2016
3rd Feb 20173:27 pmRNSHolding(s) in Company
27th Jan 20174:08 pmRNSNotice of Result & Change to Audit Committee Chair
16th Dec 20164:49 pmRNSDirector/PDMR Shareholding
16th Dec 20163:27 pmRNSHolding(s) in Company
16th Dec 20162:18 pmRNSChange of Auditor
14th Dec 20164:00 pmRNSDirector/PDMR Shareholding
13th Dec 201611:15 amRNSDirector/PDMR Shareholding
9th Dec 20165:10 pmRNSDirector/PDMR Shareholding
6th Dec 20164:21 pmRNSChange of Auditor
6th Dec 20168:18 amRNSHolding(s) in Company
2nd Dec 201612:59 pmRNSBlock listing Interim Review
1st Dec 20161:05 pmRNSTotal Voting Rights
10th Nov 20164:17 pmRNSDirector/PDMR Shareholding
9th Nov 20164:10 pmRNSDirector/PDMR Shareholding
3rd Nov 201610:42 amRNSAdditional Listing
6th Oct 20162:45 pmRNSScrip Dividend Alternative
15th Sep 20162:22 pmRNSHolding(s) in Company
12th Sep 20164:17 pmRNSDirector/PDMR Shareholding
4th Aug 20165:45 pmRNSHolding(s) in Company
4th Aug 201611:28 amRNSHolding(s) in Company
3rd Aug 20164:43 pmRNSHolding(s) in Company
3rd Aug 20162:19 pmRNSHolding(s) in Company
3rd Aug 20162:10 pmRNSHolding(s) in Company
2nd Aug 20167:00 amRNSTotal Voting Rights
26th Jul 20166:00 pmRNSDirector/PDMR Shareholding
26th Jul 20167:00 amRNSInterim results for the six months to 30 June 2016

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.